• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低剂量泊沙康唑延迟释放片用于肺移植受者的真菌预防。

Low dose posaconazole delayed release tablets for fungal prophylaxis in lung transplant recipients.

机构信息

Department of Pharmacy, UC San Diego Health, San Diego, CA, USA.

Division of Pulmonary and Critical Care Medicine, UC San Diego Health, San Diego, CA, USA.

出版信息

Clin Transplant. 2018 Aug;32(8):e13300. doi: 10.1111/ctr.13300. Epub 2018 Jun 15.

DOI:10.1111/ctr.13300
PMID:29806967
Abstract

In November 2013, posaconazole delayed release (DR) tablets were approved by the FDA with the labeled dose of 300 mg daily for fungal prophylaxis. There are no studies demonstrating the appropriate dose in lung transplant recipients (LTR). We performed a 2-center retrospective cohort study of LTR taking posaconazole DR tablets for prophylaxis between January 2014 and January 2017. Mean serum trough concentrations and percentage of measurements ≥0.7 mcg/mL were compared by daily dose. Forty-nine subjects with 156 steady state serum posaconazole concentrations were included. There was a significant difference in percentage of first measured concentration ≥0.7 mcg/mL by initial daily dose (P = .04). The mean serum posaconazole concentration by dose was 0.9 (±0.42) mcg/mL for 100 mg daily, 1.66 (±0.91) mcg/mL for 200 mg daily, 2.39 (±1.49) mcg/mL for 300 mg daily, and 1.75 (±0.21) mcg/mL for 400 mg daily (P < .001). Mean concentrations were at goal in 63.3%, 96.9%, 94.9%, and 100% of subjects taking 100 mg, 200 mg, 300 mg, and 400 mg daily respectively (P = .04). Our results suggest that doses less than 300 mg daily of posaconazole DR tablets may be adequate to achieve target serum concentrations in LTR. Larger studies are needed to confirm these findings.

摘要

2013 年 11 月,FDA 批准泊沙康唑延迟释放(DR)片剂,每日剂量为 300mg,用于真菌预防。尚无研究证明肺移植受者(LTR)的合适剂量。我们对 2014 年 1 月至 2017 年 1 月期间使用泊沙康唑 DR 片剂进行预防的 LTR 进行了一项 2 中心回顾性队列研究。按每日剂量比较平均血清谷浓度和≥0.7μg/mL 的测量值百分比。纳入了 49 例服用泊沙康唑 DR 片剂进行预防的患者,共 156 例稳定的血清泊沙康唑浓度。初始每日剂量的首次测量浓度≥0.7μg/mL 的百分比有显著差异(P=0.04)。按剂量计算的血清泊沙康唑浓度分别为 100mg 组的 0.9(±0.42)μg/mL,200mg 组的 1.66(±0.91)μg/mL,300mg 组的 2.39(±1.49)μg/mL,和 400mg 组的 1.75(±0.21)μg/mL(P<0.001)。分别接受 100mg、200mg、300mg 和 400mg 每日剂量的患者中,有 63.3%、96.9%、94.9%和 100%的患者达到目标浓度(P=0.04)。我们的结果表明,LTR 每日接受少于 300mg 的泊沙康唑 DR 片剂剂量可能足以达到目标血清浓度。需要更大的研究来证实这些发现。

相似文献

1
Low dose posaconazole delayed release tablets for fungal prophylaxis in lung transplant recipients.低剂量泊沙康唑延迟释放片用于肺移植受者的真菌预防。
Clin Transplant. 2018 Aug;32(8):e13300. doi: 10.1111/ctr.13300. Epub 2018 Jun 15.
2
Posaconazole liquid vs tablet formulation in lung transplant recipients.泊沙康唑口服液与片剂在肺移植受者中的应用。
Mycoses. 2018 Mar;61(3):186-194. doi: 10.1111/myc.12724. Epub 2017 Nov 22.
3
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.服用缓释片与口服混悬液的患者中泊沙康唑血药浓度的回顾性比较
Antimicrob Agents Chemother. 2015 Aug;59(8):4914-8. doi: 10.1128/AAC.00496-15. Epub 2015 Jun 8.
4
Co-administration of proton pump inhibitors and/or of steroids may be a risk factor for low trough concentrations of posaconazole delayed-released tablets in adult patients with haematological malignancies.质子泵抑制剂和/或类固醇的联合使用可能是血液恶性肿瘤成年患者中泊沙康唑延迟释放片谷浓度较低的一个危险因素。
Br J Clin Pharmacol. 2018 Nov;84(11):2544-2550. doi: 10.1111/bcp.13707. Epub 2018 Aug 19.
5
Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.单中心研究:肺移植受者中泊沙康唑的治疗药物监测:影响谷浓度的因素。
J Antimicrob Chemother. 2018 Mar 1;73(3):748-756. doi: 10.1093/jac/dkx440.
6
A pharmacokinetic analysis of posaconazole oral suspension in the serum and alveolar compartment of lung transplant recipients.泊沙康唑口服液在肺移植受者血清和肺泡腔中的药代动力学分析。
Int J Antimicrob Agents. 2016 Jan;47(1):69-76. doi: 10.1016/j.ijantimicag.2015.09.015. Epub 2015 Nov 1.
7
Comparison of serum concentrations between different dosing strategies of posaconazole delayed-release tablet at a large academic medical centre.泊沙康唑缓释片不同给药策略在某大型学术医疗中心的血清浓度比较
Mycoses. 2017 Apr;60(4):241-243. doi: 10.1111/myc.12587. Epub 2016 Dec 1.
8
Population Pharmacokinetics of Posaconazole Tablets and Monte Carlo Simulations To Determine whether All Patients Should Receive the Same Dose.泊沙康唑片的群体药代动力学和蒙特卡罗模拟,以确定所有患者是否应接受相同剂量。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01166-17. Print 2017 Nov.
9
Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.通过对343个疗程的分析,对泊沙康唑新片剂和静脉制剂预防侵袭性真菌感染的安全性和有效性进行实际评估
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00188-17. Print 2017 Aug.
10
Antifungal prophylactic effectiveness and intrapulmonary concentrations of voriconazole versus posaconazole in lung transplant recipients.抗真菌预防效果和伏立康唑与泊沙康唑在肺移植受者中的肺内浓度。
Med Mycol. 2022 Sep 2;60(9). doi: 10.1093/mmy/myac041.

引用本文的文献

1
Factors affecting posaconazole plasma concentrations: a meta-analysis and systematic review.影响泊沙康唑血药浓度的因素:一项荟萃分析与系统评价
Front Pharmacol. 2024 Dec 19;15:1450120. doi: 10.3389/fphar.2024.1450120. eCollection 2024.
2
Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients.肺移植受者使用唑类抗真菌药物的药理学考量综述
J Fungi (Basel). 2021 Jan 22;7(2):76. doi: 10.3390/jof7020076.
3
Traditional Chinese medicine for anti-Alzheimer's disease: berberine and evodiamine from .
用于抗阿尔茨海默病的中药:来自……的小檗碱和吴茱萸碱
Chin Med. 2020 Aug 5;15:82. doi: 10.1186/s13020-020-00359-1. eCollection 2020.